Research Interests
Real-world safety and efficacy outcomes of oncologic therapies for solid tumor malignancies, immunotherapy, oral oncolytics/targeted therapies
Overview
Joseph Elijah holds a Doctor of Pharmacy degree with Highest Distinction from the University of Michigan College of Pharmacy and a Bachelor of Science in Biological Sciences degree, graduating Summa Cum Laude from Oakland University. Dr. Elijah’s pursuit of advanced clinical and academic training continued through his completion of two comprehensive pharmacy residencies.
He successfully completed a PGY1 Pharmacy Practice Residency at the University of Michigan Health System, followed by a PGY2 Hematology/Oncology Pharmacy Residency at the Roswell Park Comprehensive Cancer Center in Buffalo, New York. Dr. Elijah’s research interests are centered around innovative approaches to oncology care. His dedication to improving patient outcomes is reflected in his focus on solid tumor oncology, immunotherapy, and oral oncolytic agents.
Dr. Elijah’s work aims to bridge the gap between clinical practice and research, as he utilizes his dual roles as an ambulatory clinical oncology pharmacist at Massachusetts General Hospital and a faculty member to explore unanswered clinical questions in the dynamic field of oncology.
Courses Taught
Comprehensive Disease Management 2 (PHMD 4621)
Comprehensive Disease Management 3 (PHMD 4631)
Comprehensive Disease Management 4 (PHMD 4641)
Cancer Chemotherapy (PHMD 4581)
Integrated Science and Therapeutics 3 (PHSC 5205)
Integrated Science and Therapeutics 7 (PHMD 5335)
Advanced Pharmacology (NRSG 5117)
Selected Publications
Elijah J, Puzanov I, Cresanti B, Hamad L, Attwood K, Catalfamo K, Riebandt G. Evaluation of Safety Outcomes Between Nivolumab Regimens with Differing Dosing Patterns. J Oncol Pharm Pract. 2024; 10781552241264817.
Elijah J, Fitzgerald L, Phan H. Use of CFTR Modulators in Special Populations, Part 1: Pregnancy and Lactation. Pediatric Pulmonology. Pediatr Pulmonol. 2023;10.1002/ppul.26706
Elijah J, Fitzgerald L, Phan H. Use of CFTR Modulators in Special Populations, Part 2: Severe Lung Disease. Pediatric Pulmonology. Pediatr Pulmonol. 2023;10.1002/ppul.26698
Kadouh N, Elijah J, Fitzgerald L, Phan H. Use of CFTR Modulators in Special Populations, Part 3: Solid Organ Transplant. Pediatric Pulmonology. Pediatr Pulmonol. 2023;10.1002/ppul.26396
Elijah J, Jain P, Holdsworth A, Baron J, Przespolewski E, Attwood K, Wang K, Billias C, Dy G. Real World Outcomes of Trilaciclib in ES-SCLC. J Clin Oncol 41. 2023 (suppl 16; abstr e20637)
Elijah J, Schepers A, Krauss J, McDevitt R. Risk Factors for Biliary Toxicity in Patients with Implanted Hepatic Artery Infusion Pumps. J Oncol Pharm Pract. 2023;10781552231158744
Elijah J, Powell K, Smith M. The Efficacy of Capsaicin on Sleep Quality and Fatigue in Fibromyalgia: A Systematic Review. J Pain Palliat Care Pharmacother. 2022; 36(2): 112-116.
Selected Public Service
- Reviewer for the Journal of Pain and Palliative Care Pharmacotherapy
- Faculty Co-advisor of Student Society of Health System Pharmacy
- Doctor of Pharmacy Admissions Committee Member
- Peer-Reviewed Journal Reviewer
- MGH Oncology P&T Subcommittee Member
